Results for this period
Interim period (second quarter)1 April 2026–30 September 2026Non-consolidated (individual)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in Thousands of yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Revenue was below the same period of the previous year due to the number of business days and the placement of consecutive holidays, while selling, general and administrative expenses increased as outsourcing expenses rose due to costs related to the transfer of production and other factors. Because subsidies and other items related to AMED’s research and development support programs were recorded as non-operating income, the increase in the ordinary loss and interim net loss was smaller than the increase in the operating loss.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (individual) |
| Period Covered | 1 April 2026–30 September 2026 |
| Net Sales | 175 Millions of yen (YoY -12.5%) |
| Operating profit | -498 Millions of yen |
| Ordinary income | -467 Millions of yen |
| Profit attributable to owners of the parent | -469 Millions of yen |
| Net income per share | -¥13.16 |
| Equity ratio | End of the current fiscal period 59.2 / End of previous period 54.1 |
| Total assets | 5,519 Millions of yen |
| Net assets | 3,278 Millions of yen |
| Cash flows from operating activities | -423,919 Thousands of yen |
| Cash flows from investing activities | -6,967 Thousands of yen |
| Cash flows from financing activities | 1,417,554 Thousands of yen |
| Cash and cash equivalents at end of period | 3,764,673 Thousands of yen |
| Full-year earnings forecast | Net Sales 1,038 Millions of yen (YoY +221.0%) / Operating profit -696 Millions of yen / Ordinary income -625 Millions of yen / Net income -628 Millions of yen |
| Annual Dividend Forecast | 0 Yen → 0 Yen（0.0%） |
| Depreciation and amortization | 14,264 Thousands of yen |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards None / Other changes None / Change in accounting estimate None / Restatement None |
| Material subsequent events | On 4 November 2026, payment and allotment were completed for the issuance of 1,000,000 common shares through a private placement and the issuance of 10,500 Series 8 stock acquisition rights. The amount raised through the new shares was ¥373 million, while the planned amount to be raised through the stock acquisition rights is ¥598.374 million. |
| Availability of Supplementary Financial Results Materials | None |
| Availability of Financial Results Briefing | Held (for institutional investors and analysts) |
| Issued Shares at Period-End | 37,034,100 shares |
| Treasury Shares at Period-End | 16,107 shares |
| Factors Behind Changes in Business Performance | Revenue was below the same period of the previous year due to the number of business days and the placement of consecutive holidays, while selling, general and administrative expenses increased as outsourcing expenses rose due to costs related to the transfer of production and other factors. Because subsidies and other items related to AMED’s research and development support programs were recorded as non-operating income, the increase in the ordinary loss and interim net loss was smaller than the increase in the operating loss. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue was below the same period of the previous year due to factors including the number of business days and the placement of consecutive holidays. The operating loss widened because outsourcing expenses increased, including costs related to the transfer of production, resulting in higher selling, general and administrative expenses. Meanwhile, because subsidies and other items related to AMED’s research and development support programs were recorded as non-operating income, the increases in the ordinary loss and interim net loss were smaller than the increase in the operating loss.